Dec 01 2024
Permanent Marker.
This list, crafted from data provided by various state regulatory agencies and Leafly, features strains celebrated for their flavor, effects, and versatility.
Continue reading
Dec 01 2024
Judge Susan Strong determined that attorneys for former State Senator John Kuehn and Secretary of State Bob Evnen failed to demonstrate a sufficient number of invalid signatures to disqualify the petitions. In a 57-page ruling, Strong noted that evidence presented showed only a few hundred invalid signatures on each petition, far below the threshold needed to declare them insufficient.
“The court finds that they have fallen short,” Strong wrote, concluding that both initiatives met the legal requirements for signature validity.
Continue reading
Nov 30 2024
There was $112,429,698 worth of legal marijuana and marijuana products sold in September in Colorado, bringing the year-to-date total to $1,060,994,048. This is according to data released today by the Colorado Department of Revenue
Of the $112.4 million in marijuana sold legally in September, $100,516,124 was purchased for recreational use, whereas medical marijuana patients purchased $11,913,574 in product. September sales resulted in $20,927,011 in tax revenue.
Continue reading
Nov 29 2024
In October, licensed marijuana stores in Massachusetts sold $138.8 million in recreational marijuana and $14.8 million in medical marijuana, totaling $153.6 million. Combined with $119 million in November sales through the 24th, the year-to-date total is now $1.5 billion, with an all-time total of $7.01 billion, according to data released today by the Massachusetts Cannabis Control Commission (CCC).
In October, average marijuana prices reached an all-time low of $4.78 per gram and $135.53 per ounce. Only Oregon has cheaper legal cannabis prices.
Continue reading
Nov 29 2024
The decision follows the voter-approved Proposition 122, which decriminalized the use, possession, and cultivation of psilocybin mushrooms, making Colorado the second state to take such a step.
Under Proposition 122, individuals aged 21 and older can legally use certain plants and fungi for personal and therapeutic purposes. Unlike marijuana legalization under Amendment 64, which allowed local jurisdictions to ban retail marijuana businesses, Proposition 122 prohibits local governments from banning natural medicine businesses. However, counties like Arapahoe retain the authority to regulate these businesses’ time, manner, and location within the bounds of state law.
Continue reading
Nov 29 2024
For the study, published on Utah.gov, researchers analyzed the impact of medical cannabis on opioid prescription rates, focusing on 186 patients with chronic pain diagnoses. The study utilized patient data from Dragonfly Wellness dispensaries and electronic health records, revealing a compelling trend of reduced opioid use following cannabis initiation.
The study found that 84.4% of participants experienced a decrease in their opioid prescriptions after beginning cannabis treatment. On average, opioid consumption, measured in Morphine Milligram Equivalents (MME) per month, dropped by 53.1%. This equated to a reduction from 3,832 MME/month before cannabis use to 1,798 MME/month afterward. Patients using cannabis products with a THC:CBD ratio of 1:0 showed the most significant reductions.
Continue reading
Nov 29 2024
Conducted by researchers from Oklahoma State University Center for Health Sciences and Universität Regensburg in Germany, the study explores the biological activity of these compounds, particularly their anti-inflammatory properties.
“Phytochemicals derived from the plant Cannabis sativa hold promise in terms of medicinal value”, states the study. “Cannabinoids such as Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN) are arguably the best characterized and known to possess wide-ranging therapeutic benefits. The mechanism of action for these therapeutic effects remains to be fully elucidated, however, the anti-inflammatory actions are of particular interest.”
Continue reading
Nov 29 2024
The measure, proposed by Kind Idaho, would decriminalize personal use and cultivation of marijuana for adults aged 21 and older if approved by voters in 2026. The secretary of state has authorized the petition for circulation, allowing organizers to begin gathering the 70,725 signatures needed to place it on the ballot. The official “short ballot title” for the proposal calls it a “Measure decriminalizing the possession, production, and cultivation of marijuana and marijuana-infused products for personal use by persons 21 or older.”
The measure would allow for the possession of up to one ounce of marijuana flower or 1,000 milligrams of THC in products like oils, tinctures, and edibles. It also allows home cultivation of up to 12 plants, with adults able to securely store up to eight ounces of marijuana harvested from those plants at home or on private property, provided it remains inaccessible to minors. Consumption in public or open settings would be prohibited.
Continue reading
Nov 29 2024
The study, published in Drug and Chemical Toxicology, highlights CBD’s potential as a protective agent against MTX-induced hepatotoxicity by targeting oxidative stress and inflammation.
The research involved 32 female Wistar Albino rats, divided into four groups: a control group, an MTX-only group, an MTX+CBD group, and a CBD-only group. The MTX+CBD group received a single dose of MTX (20 mg/kg) followed by daily CBD injections (5 mg/kg) for seven days. Researchers assessed oxidative stress markers, liver enzyme levels, and genetic expressions linked to inflammation and apoptosis.
Continue reading
Nov 29 2024
Using survey data, researchers applied a novel matched design to infer causal relationships while accounting for observational data challenges such as unequal sampling probabilities and potential confounding.
The study, published in the Biometrical Journal, found no evidence linking medical marijuana legalization to increased tolerance of DAMU. This conclusion remained robust even after sensitivity analyses were conducted to evaluate the impact of unmeasured confounding. Unlike previous studies that suggested minor associations between legalization and self-reported DAMU, this research evaluated both behaviors and attitudes using multiple survey items. The study highlighted regional differences, focusing on Southern and Midwestern states, where self-reported DAMU was rare.
Continue reading
